. Author manuscript; available in PMC: 2013 Jan 1.

Published in final edited form as: Liver Transpl. 2012 Jan;18(1):9–21. doi: 10.1002/lt.22467

Table 2.

Organizational Considerations for Review

Cell Sources	Primary hepatocytes	human adult livers (liver not transplantable, liver resections) human fetal livers healthy donor animals
	Cell lines	tumor derived (C3A, HepG2) immortalized normal hepatocytes
	Progenitor cells	Induced pluripotent stem cell (iPS cells) embryonic stem cells fetal stem cells adult stem cells (oval, mesenchymal stem cells, other)
	Hepatocyte-like	matured in vitro matured in vivo
	Other	lymphocytes, etc.

Liver Abnormality	Acute liver failure Inherited metabolic liver disease Hepatitis (alcoholic, viral) Cirrhosis (cholestatic, other) Liver cancer (hepatocellular, cholangiocarcinoma) Recurrent disease after transplantation Rejection after transplantation